Selective Serotonin Reuptake Inhibitors Bring Risk of Cataracts
06/03/2010 0 Comments
A possible association was found between future diagnosis of cataracts and selective serotonin reuptake inhibitors, says new research.
The authors of the nested case-control study evaluated a cohort of Quebec residents who had received a coronary revascularization procedure from 1995 through 2004. Cases were defined as those with the first diagnosis of a cataract diagnosed by an ophthalmologist. For each case, 10 controls were selected and matched to the cases by index date, age and cohort entry. Crude and adjusted rate ratios and corresponding confidence intervals were computed for current use of SSRIs. Rate ratios were adjusted for gender, corticosteroid use, statins, high blood pressure, antihypertensives and antidiabetics. The First International Classification for Disease (Ninth Revision) code or diagnosising cataracts was used as the main outcome measure.
Eighteen thousand seven hundred eighty-four cases and 187,840 controls met our study inclusion criteria. The adjusted rate ratios for cataracts among current users of SSRIs was 1.15 (95 percent CI, 1.08 thru 1.23). The risk of cataracts was highest with fluvoxamine (rate ratio: 1.39; 95 percent CI, 1.07 thru 1.80), followed by venlafaxine (RR, 1.33; 95% CI, 1.14 thru 1.55) and paroxetine for cataract surgery (rate ratio, 1.23; 95 percent CI, 1.05 thru 1.45). The average time to diagnosis of cataracts while on SSRI therapy was 656 days. Though the potential association was found, possibility that this observation may be the result of the effect of smoking, which could not be controlled for during the study, cannot be excluded.